All In Biotech

Drug Trial Radar · NCT07205900

Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus

A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of HM15275 for 36 Weeks in Obese or Overweight Subjects Without Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 267 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

267

Actual

Start

Dec 2, 2025

Primary completion

Jan 2027

Study completion Jan 2027

Sponsor

Sponsor type
Industry
First posted
Oct 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Study is a Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of HM15275 for 36 Weeks in Obese or Overweight Subjects Without Diabetes Mellitus.

Conditions

  • Obese
  • Obesity

Interventions

  • HM15275Drug

    HM15275 is a sterile solution for subcutaneous injection, supplied pre-filled syringes.

  • Placebo of HM15275Drug

    A sterile, matching solution supplied in pre-filled syringes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change in Body Weight.Time frame: Up to 41 weeks

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • ProSciento Inc

    Chula Vista, California

  • Accellacare of Duly - Duly Oak Lawn

    Oak Lawn, Illinois

  • Accellacare of McFarland

    Ames, Iowa

  • Accellacare of Cary - Cary Medical Group

    Cary, North Carolina

  • Accellacare of Hickory

    Hickory, North Carolina

  • Raleigh Medical Group, P.A.

    Raleigh, North Carolina

  • Accellacare of Piedmont - Piedmont HealthCare

    Statesville, North Carolina

  • Accellacare of Wilmington, LLC

    Wilmington, North Carolina

  • Accellacare of Winston Salem

    Winston-Salem, North Carolina

  • Accellacare of Charleston

    Mt. Pleasant, South Carolina

  • Accellacare of Bristol-PAC of Tennessee

    Bristol, Tennessee

  • Bristol-Internal Medicine and Pediatric Associates of Bristol, P.C.

    Bristol, Tennessee

  • Texas Clinical Research Institute

    Arlington, Texas

  • Velocity Clinical Research, Dallas

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.